AU2001258614A1 - Diagnostic method for alzheimer's disease based on holo-transcobalamin ii - Google Patents

Diagnostic method for alzheimer's disease based on holo-transcobalamin ii

Info

Publication number
AU2001258614A1
AU2001258614A1 AU2001258614A AU5861401A AU2001258614A1 AU 2001258614 A1 AU2001258614 A1 AU 2001258614A1 AU 2001258614 A AU2001258614 A AU 2001258614A AU 5861401 A AU5861401 A AU 5861401A AU 2001258614 A1 AU2001258614 A1 AU 2001258614A1
Authority
AU
Australia
Prior art keywords
holo
alzheimer
transcobalamin
diagnostic method
disease based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258614A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axis Shield ASA
Original Assignee
Axis Shield ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield ASA filed Critical Axis Shield ASA
Publication of AU2001258614A1 publication Critical patent/AU2001258614A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a diagnostic or prognostic assay method for Alzheimer's Disease by assaying a body fluid sample or a test sample derived therefrom for holo-trancobalamin II.
AU2001258614A 2000-07-04 2001-05-22 Diagnostic method for alzheimer's disease based on holo-transcobalamin ii Abandoned AU2001258614A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0016460 2000-07-04
GBGB0016460.8A GB0016460D0 (en) 2000-07-04 2000-07-04 Assay
PCT/GB2001/002306 WO2002003074A1 (en) 2000-07-04 2001-05-22 Diagnostic method for alzheimer's disease based on holo-transcobalamin ii

Publications (1)

Publication Number Publication Date
AU2001258614A1 true AU2001258614A1 (en) 2002-01-14

Family

ID=9895035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258614A Abandoned AU2001258614A1 (en) 2000-07-04 2001-05-22 Diagnostic method for alzheimer's disease based on holo-transcobalamin ii

Country Status (11)

Country Link
US (1) US7294514B2 (en)
EP (1) EP1297342B1 (en)
JP (1) JP2004502940A (en)
AT (1) ATE302416T1 (en)
AU (1) AU2001258614A1 (en)
DE (1) DE60112758T2 (en)
DK (1) DK1297342T3 (en)
ES (1) ES2249432T3 (en)
GB (1) GB0016460D0 (en)
PT (1) PT1297342E (en)
WO (1) WO2002003074A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065449A1 (en) 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
WO2018188771A1 (en) * 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
AU2017408873A1 (en) * 2017-04-11 2019-08-29 Societe Des Produits Nestle S.A. Omega-3 fatty acid and vitamin D levels to identify and attenuate cognitive aging in individuals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273757A (en) * 1977-06-02 1981-06-16 Yissum Research Development Company Determination of transcobalamins
US4680273A (en) * 1985-07-29 1987-07-14 Victor Herbert Assay for vitamin B12 deficiency
WO2000011479A1 (en) * 1998-08-20 2000-03-02 Axis-Shield Asa Assay method for cardiovascular disease
GB9820473D0 (en) * 1998-09-18 1998-11-11 Axis Biochemicals Asa Assay

Also Published As

Publication number Publication date
US20040014230A1 (en) 2004-01-22
US7294514B2 (en) 2007-11-13
DK1297342T3 (en) 2005-12-19
DE60112758D1 (en) 2005-09-22
DE60112758T2 (en) 2006-06-29
GB0016460D0 (en) 2000-08-23
PT1297342E (en) 2005-10-31
EP1297342A1 (en) 2003-04-02
WO2002003074A1 (en) 2002-01-10
JP2004502940A (en) 2004-01-29
ES2249432T3 (en) 2006-04-01
ATE302416T1 (en) 2005-09-15
EP1297342B1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
EP1521083A3 (en) Method for diagnosing and distinguishing stroke
CA2366778A1 (en) Methods for detecting nucleic acids indicative of cancer
HK1036834A1 (en) Differential diagnosis of neurodegeneration
EP0987550A3 (en) Analytical test device and method of use
EP0915173A3 (en) Kit and method for fluorescence based detection assay
EP2251695A3 (en) Markers associated with endometrial disease
AU9066998A (en) Use of check surfaces for identifying disturbing samples in a detection procedure
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2002059379A3 (en) Methods for detecting, grading or monitoring an $i(h. pylori) infection
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
EP1365862B8 (en) Biological fluid analysis device
BR0014150A (en) Diagnostics and therapeutics for osteoporosis
MXPA01005698A (en) Assay for anti transglutaminase antibodies detection useful in celiac disease diagnosis.
WO2002059617A3 (en) Standard diluent for multiplex assays
AU2001258614A1 (en) Diagnostic method for alzheimer's disease based on holo-transcobalamin ii
CA2172243A1 (en) Method for quantifying bpi in body fluids
ATE275268T1 (en) METHOD FOR DIAGNOSIS OF SJÖGREN'S SYNDROME
CA2415364A1 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
EP1312613A3 (en) (1--3)-beta-D-glucan binding domain protein, measuring method using the substance and assay kit
AU2001289547A1 (en) Method for determining the age of individuals
AU2002366555A1 (en) Diagnostic for early stage alzheimer's disease
AU1690899A (en) Method for testing crohn's disease and testing kit therefor
WO2002050543A3 (en) Free analyte detection system
WO2003054547A3 (en) Diagnosis of dementia utilizing thrombospondin
WO2003104812A3 (en) DIAGNOSIS OF ALZHEIMER'S DISEASE BASED ON THE hAbeta42:hAbeta40 RATIO